We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Deep Transcranial Magnetic Stimulation Reduces Symptoms of Fatigue in MS Patients
News

Deep Transcranial Magnetic Stimulation Reduces Symptoms of Fatigue in MS Patients

Deep Transcranial Magnetic Stimulation Reduces Symptoms of Fatigue in MS Patients
News

Deep Transcranial Magnetic Stimulation Reduces Symptoms of Fatigue in MS Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Deep Transcranial Magnetic Stimulation Reduces Symptoms of Fatigue in MS Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A pilot study conducted by researchers from Charité’s NeuroCure Cluster of Excellence has shown that treatment with deep transcranial magnetic stimulation (dTMS) significantly reduces symptoms of fatigue in patients with multiple sclerosis (MS). Published in the current issue of the journal Neurology: Neuroimmunology & Neuroinflammation, results from this research suggest that TMS is a safe option for the treatment of patients with MS.

Up to 90 percent of people living with MS report experiencing severe fatigue. Fatigue can have a serious impact on both a person's work and social life, and leads many patients to give up work. In fact, a large percentage of people with MS rate fatigue as one of the most bothersome symptoms of the disease. Treatment options are scarce, and no licensed pharmaceutical treatments are available. In contrast, dTMS has been used in the diagnosis and treatment of a range of neurological and psychiatric disorders.


A team of researchers, led by Prof. Dr. Friedemann Paul of the NeuroCure Clinical Research Center (NCRC), has shown that dTMS, using the proprietary H-coil, a technology that allows brain stimulation three times deeper than that of standard TMS, is capable of producing significant improvements in fatigue symptoms. The severity of MS-associated symptoms was assessed using a standardized questionnaire and the Fatigue Severity Scale (FSS). 33 study participants with fatigue received thrice-weekly sessions of dTMS for a duration of six weeks; this involves a stimulation H-coil being placed above the patient’s head, which generates a magnetic field that influences nerve activity and neural circuits in the brain. A control group received a sham treatment.


“We observed no serious side effects in patients treated with dTMS, and it is therefore worth stressing the tolerability of this noninvasive electrophysiological technique,” says Prof. Paul, the study’s principal investigator. Further, it is also worth noting that the treatment was delivered using a new type of H-coil, which had been developed specifically for use in this study. This coil permits the targeted stimulation of areas of the brain which, according to the latest research, play a major role in MS-associated fatigue. A follow-up study involving a larger number of participants is being planned. This is intended to verify the efficacy of this treatment method, and to help ensure the implementation of dTMS for MS-associated fatigue into routine clinical practice. "We are excited about the collaboration between Prof. Dr. Friedemann Paul and his team at Charité’s NeuroCure and Brainsway for studying the use of our patented Deep TMS technology for the benefit of MS patients, a new neurological field for us. These promising results of relieving the very hard to treat fatigue symptoms in MS, brings a new hope for being able to provide a solution for the many patients who need it." Says Ronen Segal, CTO of Brainsway LTD.


This article has been republished from materials provided by Charité University of Medicine, Berlin. Note: material may have been edited for length and content. For further information, please contact the cited source.


Reference:

Gaede, G., M. Tiede, I. Lorenz, A. U. Brandt, C. Pfueller, J. Dorr, J. Bellmann-Strobl, S. K. Piper, Y. Roth, A. Zangen, S. Schippling, and F. Paul. "Safety and Preliminary Efficacy of Deep Transcranial Magnetic Stimulation in Ms-Related Fatigue." Neurol Neuroimmunol Neuroinflamm 5, no. 1 (Jan 2018): e423. http://dx.doi.org/10.1212/nxi.0000000000000423.


Advertisement